Analysts’ Top Healthcare Picks: Ligand Pharma (LGND), MiMedx Group (MDXG)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ligand Pharma (LGND – Research Report), MiMedx Group (MDXG – Research Report) and Novan (NOVN – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Ligand Pharma (LGND)
Craig-Hallum analyst Matt Hewitt maintained a Buy rating on Ligand Pharma today. The company’s shares closed last Tuesday at $191.45.
According to TipRanks.com, Hewitt is a 3-star analyst with an average return of
Currently, the analyst consensus on Ligand Pharma is a Strong Buy with an average price target of $243.50, a 26.2% upside from current levels. In a report issued on December 9, Citi also initiated coverage with a Buy rating on the stock with a $270.00 price target.
See today’s best-performing stocks on TipRanks >>
MiMedx Group (MDXG)
Craig-Hallum analyst Chase Knickerbocker maintained a Buy rating on MiMedx Group today. The company’s shares closed last Tuesday at $7.08.
According to TipRanks.com, Knickerbocker is a top 100 analyst with an average return of
MiMedx Group has an analyst consensus of Strong Buy, with a price target consensus of $12.00, which is a 68.5% upside from current levels. In a report issued on December 7, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $7.50 price target.
